Stock Track | Ginkgo Bioworks Plunges 12.63% After-Hours on Weak 2025 Outlook and Restructuring Costs

Stock Track

Feb 26, 2025

Shares of Ginkgo Bioworks Holdings Inc. (DNA) plunged 12.63% in after-hours trading on Tuesday, following the release of the company's fourth quarter and full-year 2024 financial results. The biotechnology company reported a wider net loss and provided a disappointing revenue outlook for 2025, citing ongoing restructuring efforts and challenges in its Biosecurity segment.

The key factors contributing to Ginkgo Bioworks' after-hours slump are:
1. Weak 2025 Revenue Guidance: The company expects total revenue of $160-$180 million in 2025, lower than analysts' expectations, with its Biosecurity segment facing potential headwinds due to government funding availability.
2. Ongoing Restructuring Costs: Ginkgo incurred $24.2 million in restructuring charges in 2024, including employee termination costs and impairment of lease assets, as part of its plan to achieve cost reductions and reach profitability by 2026.
3. Tepid Biosecurity Performance: The Biosecurity segment reported a 51% year-over-year decline in revenue to $53 million in 2024, impacted by a transition from K-12 testing to a more recurring business model.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1108513353"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108513353\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108513353?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 06:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108513353","market":"us","top_or_hot":-1,"title":"Stock Track | Ginkgo Bioworks Plunges 12.63% After-Hours on Weak 2025 Outlook and Restructuring Costs","media":"Stock Track","content":"<p>Shares of Ginkgo Bioworks Holdings Inc. (DNA) plunged 12.63% in after-hours trading on Tuesday, following the release of the company's fourth quarter and full-year 2024 financial results. The biotechnology company reported a wider net loss and provided a disappointing revenue outlook for 2025, citing ongoing restructuring efforts and challenges in its Biosecurity segment.</p>\n\n<p>The key factors contributing to Ginkgo Bioworks' after-hours slump are:\n<br>1. Weak 2025 Revenue Guidance: The company expects total revenue of $160-$180 million in 2025, lower than analysts' expectations, with its Biosecurity segment facing potential headwinds due to government funding availability.\n<br>2. Ongoing Restructuring Costs: Ginkgo incurred $24.2 million in restructuring charges in 2024, including employee termination costs and impairment of lease assets, as part of its plan to achieve cost reductions and reach profitability by 2026.\n<br>3. Tepid Biosecurity Performance: The Biosecurity segment reported a 51% year-over-year decline in revenue to $53 million in 2024, impacted by a transition from K-12 testing to a more recurring business model.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ginkgo Bioworks Plunges 12.63% After-Hours on Weak 2025 Outlook and Restructuring Costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ginkgo Bioworks Plunges 12.63% After-Hours on Weak 2025 Outlook and Restructuring Costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 06:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Ginkgo Bioworks Holdings Inc. (DNA) plunged 12.63% in after-hours trading on Tuesday, following the release of the company's fourth quarter and full-year 2024 financial results. The biotechnology company reported a wider net loss and provided a disappointing revenue outlook for 2025, citing ongoing restructuring efforts and challenges in its Biosecurity segment.</p>\n\n<p>The key factors contributing to Ginkgo Bioworks' after-hours slump are:\n<br>1. Weak 2025 Revenue Guidance: The company expects total revenue of $160-$180 million in 2025, lower than analysts' expectations, with its Biosecurity segment facing potential headwinds due to government funding availability.\n<br>2. Ongoing Restructuring Costs: Ginkgo incurred $24.2 million in restructuring charges in 2024, including employee termination costs and impairment of lease assets, as part of its plan to achieve cost reductions and reach profitability by 2026.\n<br>3. Tepid Biosecurity Performance: The Biosecurity segment reported a 51% year-over-year decline in revenue to $53 million in 2024, impacted by a transition from K-12 testing to a more recurring business model.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNA","symbol_name":"Ginkgo Bioworks Holdings Inc.","start_time":0,"source_url":"","article_id":"1108513353","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108513353","pubTimestamp":1740521205,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ginkgo Bioworks Holdings Inc.  plunged 12.63% in after-hours trading on Tuesday, following the release of the company's fourth quarter and full-year 2024 financial results. The biotechnology company reported a wider net loss and provided a disappointing revenue outlook for 2025, citing ongoing restructuring efforts and challenges in its Biosecurity segment.The key factors contributing to Ginkgo Bioworks' after-hours slump are:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNA":"Ginkgo Bioworks Holdings Inc."},"translate_title":"股票赛道Ginkgo Bioworks盘后暴跌12.63%，原因是2025年前景疲软和重组成本","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNA":1},"content_text":"Shares of Ginkgo Bioworks Holdings Inc. (DNA) plunged 12.63% in after-hours trading on Tuesday, following the release of the company's fourth quarter and full-year 2024 financial results. The biotechnology company reported a wider net loss and provided a disappointing revenue outlook for 2025, citing ongoing restructuring efforts and challenges in its Biosecurity segment.\nThe key factors contributing to Ginkgo Bioworks' after-hours slump are:\n1. Weak 2025 Revenue Guidance: The company expects total revenue of $160-$180 million in 2025, lower than analysts' expectations, with its Biosecurity segment facing potential headwinds due to government funding availability.\n2. Ongoing Restructuring Costs: Ginkgo incurred $24.2 million in restructuring charges in 2024, including employee termination costs and impairment of lease assets, as part of its plan to achieve cost reductions and reach profitability by 2026.\n3. Tepid Biosecurity Performance: The Biosecurity segment reported a 51% year-over-year decline in revenue to $53 million in 2024, impacted by a transition from K-12 testing to a more recurring business model.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}